Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (2): 176-179.doi: 10.11958/20220487
• Clinical Research • Previous Articles Next Articles
XU Xuemei(), LI Chunyan, DENG Zhihong, XU Xiaoming, SHI Jing
Received:
2022-03-31
Revised:
2022-05-17
Published:
2023-02-15
Online:
2023-02-24
XU Xuemei, LI Chunyan, DENG Zhihong, XU Xiaoming, SHI Jing. Analysis of macular choroidal thickness in patients with grade 3 essential hypertension[J]. Tianjin Medical Journal, 2023, 51(2): 176-179.
CLC Number:
组别 | n | 眼压(mmHg) | 等效球径(D) | 眼轴(mm) |
---|---|---|---|---|
正常组 | 58 | 15.55±1.97 | -1.06±0.72 | 23.37±0.63 |
高血压组 | 56 | 15.64±2.09 | -1.08±0.74 | 23.41±0.90 |
t | 0.169 | 0.140 | 0.279 |
Tab.1 2组患者一般资料比较 ($\bar{x}±s$)
组别 | n | 眼压(mmHg) | 等效球径(D) | 眼轴(mm) |
---|---|---|---|---|
正常组 | 58 | 15.55±1.97 | -1.06±0.72 | 23.37±0.63 |
高血压组 | 56 | 15.64±2.09 | -1.08±0.74 | 23.41±0.90 |
t | 0.169 | 0.140 | 0.279 |
组别 | n | 中心区 | S3 | T3 | I3 | N3 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 217.03±44.07 | 210.24±45.96 | 214.38±44.02 | 202.76±49.83 | 174.16±48.61abcd | |||||
高血压组 | 56 | 189.80±48.53 | 191.23±50.90 | 184.96±42.83 | 181.64±46.68 | 165.50±53.05abc | |||||
t | 3.138** | 2.094* | 3.614** | 2.333* | 0.909 | ||||||
组别 | S6 | T6 | I6 | N6 | F | ||||||
正常组 | 205.19±47.28e | 197.19±42.19e | 187.79±42.08a | 144.22±37.05abcdefgh | 15.686** | ||||||
高血压组 | 186.75±47.18e | 181.14±39.51 | 170.88±42.88 | 132.66±43.66abcdefgh | 8.783** | ||||||
t | 2.084* | 2.094* | 2.126* | 1.527 |
Tab.2 2组黄斑各区脉络膜厚度比较 (μm,$\bar{x}±s$)
组别 | n | 中心区 | S3 | T3 | I3 | N3 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 217.03±44.07 | 210.24±45.96 | 214.38±44.02 | 202.76±49.83 | 174.16±48.61abcd | |||||
高血压组 | 56 | 189.80±48.53 | 191.23±50.90 | 184.96±42.83 | 181.64±46.68 | 165.50±53.05abc | |||||
t | 3.138** | 2.094* | 3.614** | 2.333* | 0.909 | ||||||
组别 | S6 | T6 | I6 | N6 | F | ||||||
正常组 | 205.19±47.28e | 197.19±42.19e | 187.79±42.08a | 144.22±37.05abcdefgh | 15.686** | ||||||
高血压组 | 186.75±47.18e | 181.14±39.51 | 170.88±42.88 | 132.66±43.66abcdefgh | 8.783** | ||||||
t | 2.084* | 2.094* | 2.126* | 1.527 |
组别 | n | 中心区 | S3 | T3 | I3 | N3 | S6 | T6 | I6 | N6 |
---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 259.33±16.55 | 335.60±21.56 | 322.43±20.05 | 332.87±16.20 | 336.21±17.29 | 307.71±20.15 | 287.66±20.66 | 299.60±12.64 | 317.27±13.22 |
高血压组 | 56 | 254.52±19.64 | 333.45±14.94 | 320.64±15.86 | 327.95±14.17 | 333.89±13.50 | 203.63±16.31 | 285.20±18.11 | 292.79±12.76 | 306.84±14.68 |
t | 1.415 | 0.619 | 0.527 | 1.728 | 0.795 | 1.186 | 0.675 | 2.865** | 3.992** |
Tab.3 2组黄斑各区视网膜厚度比较 (μm,$\bar{x}±s$)
组别 | n | 中心区 | S3 | T3 | I3 | N3 | S6 | T6 | I6 | N6 |
---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 259.33±16.55 | 335.60±21.56 | 322.43±20.05 | 332.87±16.20 | 336.21±17.29 | 307.71±20.15 | 287.66±20.66 | 299.60±12.64 | 317.27±13.22 |
高血压组 | 56 | 254.52±19.64 | 333.45±14.94 | 320.64±15.86 | 327.95±14.17 | 333.89±13.50 | 203.63±16.31 | 285.20±18.11 | 292.79±12.76 | 306.84±14.68 |
t | 1.415 | 0.619 | 0.527 | 1.728 | 0.795 | 1.186 | 0.675 | 2.865** | 3.992** |
组别 | n | 中心区 | S3 | T3 | I3 | N3 | S6 | T6 | I6 | N6 |
---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 0.025 | -0.523 | -0.101 | -0.041 | -0.079 | 0.033 | 0.095 | 0.001 | 0.129 |
高血压组 | 56 | 0.140 | 0.303* | 0.194 | 0.147 | 0.177 | 0.322* | 0.217 | 0.063 | 0.112 |
Tab.4 2组黄斑各区脉络膜厚度与视网膜厚度相关性 (r)
组别 | n | 中心区 | S3 | T3 | I3 | N3 | S6 | T6 | I6 | N6 |
---|---|---|---|---|---|---|---|---|---|---|
正常组 | 58 | 0.025 | -0.523 | -0.101 | -0.041 | -0.079 | 0.033 | 0.095 | 0.001 | 0.129 |
高血压组 | 56 | 0.140 | 0.303* | 0.194 | 0.147 | 0.177 | 0.322* | 0.217 | 0.063 | 0.112 |
分区 | 正常组 | 高血压组 | ||||||
---|---|---|---|---|---|---|---|---|
R2 | 调整后R2 | β | t | R2 | 调整后R2 | β | t | |
中心区 | 0.193 | 0.179 | -2.778 | -3.662** | 0.095 | 0.078 | -2.082 | -2.378* |
S3 | 0.237 | 0.223 | -3.206 | -3.752** | 0.082 | 0.065 | -2.025 | -2.189* |
T3 | 0.208 | 0.194 | -2.877 | -3.831** | 0.134 | 0.118 | -2.182 | -2.887** |
I3 | 0.226 | 0.213 | -3.400 | -4.048** | 0.130 | 0.114 | -2.343 | -2.838** |
N3 | 0.201 | 0.187 | -3.124 | -3.752** | 0.044 | 0.026 | -1.554 | -1.580 |
S6 | 0.145 | 0.130 | -2.584 | -3.084** | 0.119 | 0.102 | -2.264 | -2.696** |
T6 | 0.230 | 0.217 | -2.904 | -4.095** | 0.170 | 0.155 | -2.270 | -3.325** |
I6 | 0.299 | 0.287 | -3.301 | -4.889** | 0.108 | 0.092 | -1.965 | -2.559* |
N6 | 0.146 | 0.131 | -2.029 | -3.093** | 0.091 | 0.074 | -1.836 | -2.326* |
Tab.5 年龄对黄斑各区脉络膜厚度的影响的线性回归分析
分区 | 正常组 | 高血压组 | ||||||
---|---|---|---|---|---|---|---|---|
R2 | 调整后R2 | β | t | R2 | 调整后R2 | β | t | |
中心区 | 0.193 | 0.179 | -2.778 | -3.662** | 0.095 | 0.078 | -2.082 | -2.378* |
S3 | 0.237 | 0.223 | -3.206 | -3.752** | 0.082 | 0.065 | -2.025 | -2.189* |
T3 | 0.208 | 0.194 | -2.877 | -3.831** | 0.134 | 0.118 | -2.182 | -2.887** |
I3 | 0.226 | 0.213 | -3.400 | -4.048** | 0.130 | 0.114 | -2.343 | -2.838** |
N3 | 0.201 | 0.187 | -3.124 | -3.752** | 0.044 | 0.026 | -1.554 | -1.580 |
S6 | 0.145 | 0.130 | -2.584 | -3.084** | 0.119 | 0.102 | -2.264 | -2.696** |
T6 | 0.230 | 0.217 | -2.904 | -4.095** | 0.170 | 0.155 | -2.270 | -3.325** |
I6 | 0.299 | 0.287 | -3.301 | -4.889** | 0.108 | 0.092 | -1.965 | -2.559* |
N6 | 0.146 | 0.131 | -2.029 | -3.093** | 0.091 | 0.074 | -1.836 | -2.326* |
[1] | UNGER T, BORGHI C, CHARCHAR F, et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6):982-1004. doi:10.1097/HJH.0000000000002453. |
[2] | MITTAL B V, SINGH A K. Hypertension in the developing world:challenges and opportunities[J]. Am J Kidney Dis, 2010, 55(3):590-598. doi:10.1053/j.ajkd.2009.06.044. |
[3] | 马宁, 李威, 刘钰君, 等. 无明确高血压视网膜病变患者黄斑区血流密度观察[J]. 中华眼底病杂志, 2020, 36(5):358-361. |
MA N, LI W, LIU Y J, et al. The macular vascular density in hypertensive patients without obvious hypertensive retinopathy[J]. Chin J Ocul Fundus Dis, 2020, 36(5):358-360. doi:10.3760/cma.j.cn511434-20190424-00156. | |
[4] | KATSI V, VLACHOPOULOS C, SOURETIS G, et al. Association between retinal microcirculation and aortic stiffness in hypertensive patients[J]. Int J Cardiol, 2012, 157(3):370-373. doi:10.1016/j.ijcard.2010.12.074. |
[5] | 何吕福. 脉络膜厚度研究进展[J]. 中华实验眼科杂志, 2017, 35(10):949-954. |
HE L F. Review on progress of choroidal thickness[J]. Chin J Exp Ophthalmol, 2017, 35(10):949-954. doi:10.3760/cma.j.issn.2095-0160.2017.10.021. | |
[6] | 周莹, 葛芹玉, 贾二腾. 影响脉络膜厚度的因素[J]. 国际眼科杂志, 2019, 19(12):2001-2006. |
ZHOU Y, GE Q Y, JIA E T. Factors affecting choroidal thickness[J]. Int Eye Sci, 2019, 19(12):2001-2006. doi:10.3980/j.issn.1672-5123.2019.12.01. | |
[7] | FAWZI A A, PAPPURU R R, SARRAF D, et al. Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging[J]. Retina, 2012, 32(8):1500-1513. doi:10.1097/IAE.0b013e318263d0c3. |
[8] | 黎遂林, 李慧丽, 杨娇, 等. 视网膜分支静脉阻塞患者的脉络膜厚度及血流密度分析[J]. 临床医学研究与实践, 2021, 6(11):101-103. |
LI S L, LI H L, YANG J. Analysis of choroidal thickness and blood flow density in patients with branch retinal vein occlusion[J]. Clinical Research and Practice, 2021, 6(11):101-103. doi:10.19347/j.cnki.2096-1413.202111036. | |
[9] | 王磊, 魏新伟, 于芳. 不同降压药物联合治疗对老年高血压患者血压变异性的影响[J]. 天津医药, 2016, 44(1):105-109. |
WANG L, WEI X W, YU F. Effects of combined treatment of different anti-hypertensive drugs on blood pressure variability in elderly patients with hypertension[J]. Tianjin Med J, 2016, 44(1):105-109. doi:10.11958/58650. | |
[10] | KATSI V, VLACHOPOULOS C, SOURETIS G, et al. Association between retinal microcirculation and aortic stiffness in hypertensive patients[J]. Int J Cardiol, 2012, 157(3):370-373. doi:10.1016/j.ijcard.2010.12.074. |
[11] | 张承芬, 董方田, 陈有信, 等. 眼底病学[M]. 2版. 北京: 人民卫生出版社, 2010:15. |
ZHANG C F, DONG F T, CHEN Y X, et al. Diseases of Ocular Fundus[M]. 2nd Ed. Beijing: People's Medical Publishing House, 2010:15. | |
[12] | 惠延年. 视网膜脉络膜血管特征性改变作为系统性疾病生物标志物及其预警作用[J]. 眼科, 2019, 28(3):161-164. |
HUI Y N. Characteristic features of retinal and choroidal vasculatures as biomarkers and warning for systemic diseas[J]. Ophthalmol CHN, 2019, 28(3):161-164. doi:10.13281/j.cnki.issn.1004-4469.2019.03.001. | |
[13] | LEE H M, LEE W H, KIM K N, et al. Changes in thickness of central macula and retinal nerve fibre layer in severe hypertensive retinopathy:a 1-year longitudinal study[J]. Acta Ophthalmol, 2018, 96(3):e386-e392. doi:10.1111/aos.13521. |
[14] | USUI S, IKUNO Y, AKIBA M, et al. Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects[J]. Invest Ophthalmol Vis Sci, 2012, 53(4):2300-2307. doi:10.1167/iovs.11-8383. |
[15] | REINER A, FITZGERALD M, DEL MAR N, et al. Neural control of choroidal blood flow[J]. Prog Retin Eye Res, 2018, 64:96-130. doi:10.1016/j.preteyeres.2017.12.001. |
[16] | AKAY F, GUNDOGAN F C, YOLCU U, et al. Choroidal thickness in systemic arterial hypertension[J]. Eur J Ophthalmol, 2016, 26(2):152-157. doi:10.5301/ejo.5000675. |
[17] | GÖK M, KARABAS V L, EMRE E, et al. Evaluation of choroidal thickness via enhanced depth-imaging optical coherence tomography in patients with systemic hypertension[J]. Indian J Ophthalmol, 2015, 63(3):239-243. doi:10.4103/0301-4738.156928. |
[18] | 李略, 杨治坤, 董方田. 应用增强深部成像的相干光断层扫描测量正常人脉络膜厚度[J]. 中华眼科杂志, 2012, 48(9):819-823. |
LI L, YANG Z K, DONG F T. Choroidal thickness in normal subjects measured by enhanced depth imaging optical coherence tomography[J]. Chin J Ophthalmol, 2012, 48(9):819-823. doi:10.3760/cma.j.issn.0412-4081.2012.09.012. | |
[19] | WEI W B, XU L, JONAS J B, et al. Subfoveal choroidal thickness:the Beijing Eye Study[J]. Ophthalmology, 2013, 120(1):175-180. doi:10.1016/j.ophtha.2012.07.048. |
[20] | BROADHEAD G K, HONG T, MCCLUSKEY P, et al. Choroidal thickness and microperimetry sensitivity in age-related macular degeneration[J]. Ophthalmic Res, 2017, 58(1):27-34. doi:10.1159/000464447. |
[21] | LEE W H, PARK J H, WON Y, et al. Retinal microvascular change in hypertension as measured by optical coherence tomography angiography[J]. Sci Rep, 2019, 9(1):156. doi:10.1038/s41598-018-36474-1. |
[1] | MA Liang, HU Liying, SHI Yu, LONG Gang. Application of optical coherence tomography angiography in clinical evaluation of chronic kidney disease [J]. Tianjin Medical Journal, 2024, 52(8): 882-887. |
[2] | WU Caixin, YAN Yan, DENG Yuanlin, DU Yamin, YANG Zhenwen, PAN Qing, YANG Fan. The value of cardiac magnetic resonance in evaluating severe pulmonary hypertension associated with connective tissue disease [J]. Tianjin Medical Journal, 2024, 52(7): 691-694. |
[3] | WANG Hui, PAN Qing, WANG Zhouming, ZHANG Na, YANG Zhenwen, WEI Wei. Analysis of clinical features of mixed connective tissue disease associated with pulmonary arterial hypertension [J]. Tianjin Medical Journal, 2024, 52(7): 701-703. |
[4] | CHEN Yujie, HUANG Xia, DENG Bolin, JIA Wenwen. Effects of acacetin on angiogenesis in diabetes retinopathy rats by regulating Hippo signaling pathway [J]. Tianjin Medical Journal, 2024, 52(6): 578-583. |
[5] | LI Yong, SU Yakun, ZHANG Hongbo, LI Yuan, LI Zhanhu, YAN Xiaoju. Clinical significance of serum asprosin level in patients with early renal damage of essential hypertension [J]. Tianjin Medical Journal, 2024, 52(6): 609-613. |
[6] | ZHENG Kangpeng, TANG Xinguo, XU Qi, FAN Yuting, LIANG Bo, FU Xiaowei, FANG Lu. Nomogram construction and validation for predicting the possibility successful implementation of radical surgery in gallbladder cancer patients [J]. Tianjin Medical Journal, 2024, 52(5): 536-540. |
[7] | ZHANG Liran, ZHAO Yanhua. The predictive value of MP hypertension monitoring system combined with PLGF and PI for preeclampsia [J]. Tianjin Medical Journal, 2024, 52(3): 306-310. |
[8] | CAO Junyang, MA Chunxing, LIU Zhina. Predictive value of vitamin and folic acid levels in gestational diabetes mellitus complicated by preeclampsia [J]. Tianjin Medical Journal, 2024, 52(12): 1278-1282. |
[9] | QIN Chundi, MA Wen, LI Yuan, ZHU Yaquan, LI Yu, ZOU Lin, ZHANG Xin. Butyrate reduces blood pressure in hypertensive rats by activating the G protein-coupled receptor 41/43 pathway [J]. Tianjin Medical Journal, 2023, 51(9): 972-976. |
[10] | GUO Yufeng, LIU Yumei, BI Xiuzeng, GUO Junlin, SUN Li, WANG Weixiu, YANG Dingwei. Correlation between macular retinal thickness and urinary protein in adult patients with nephrotic syndrome [J]. Tianjin Medical Journal, 2023, 51(8): 869-872. |
[11] | ZHANG Zhaoxia, NAN Xingmei, LI Zhanqiang, LU Dianxiang. Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2023, 51(8): 892-896. |
[12] | ZHANG Wenjing, WEN Dehui, ZHENG Yingjuan, LI Chaoxi, NIU Yajun, MIAO Qing. The study of QAS combined with QIMT technology on carotid atherosclerosis in patients with normal high blood pressure [J]. Tianjin Medical Journal, 2023, 51(6): 662-667. |
[13] | ZHENG Yue, MA Yunting, ZHAO Xiaoying, ZHAO Xinxiang. Correlation between homocysteine and left ventricular myocardial fibrosis in hypertensive patients [J]. Tianjin Medical Journal, 2023, 51(4): 395-399. |
[14] | BI Meng, FAN Fang, JIA Zhiyang. Research progress in clinical application of choroid capillary flow deficits [J]. Tianjin Medical Journal, 2023, 51(4): 445-448. |
[15] | LU Rongzhen, HUANG Jiangnan, PAN Xingshou, LU Ting, LI Jindu, LI Tianzi, TAN Shuhan. Application effect research of different antihypertensive modes in elderly hypertensive patients with coronary heart disease and PCI [J]. Tianjin Medical Journal, 2023, 51(3): 277-281. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||